TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a multi-center, single-arm, open-label, Phase II clinical trial which explores the safety and efficacy of TGRX-326 in patients with ALK-positive advanced NSCLC who have failed prior 2nd-generation ALK treatments due to progressive disease or intolerance.
Phase:
PHASE2
Details
Lead Sponsor:
Shenzhen TargetRx, Inc.
Collaborators:
Affiliated Cancer Hospital of Guizhou Medical University Bingzhou Medical University Affiliated Hospital Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center Capital Medical School Beijing Chest Hospital First Affiliated Hospital of Bengbu Medical College First Affiliated Hospital Xi'an Jiaotong University First Affiliated Hospital, Sun Yat-Sen University First Hospital of China Medical University Fujian Cancer Hospital Haerbin Medical University Cancer Hospital Henan Cancer Hospital Hunan Cancer Hospital Jiangxi Provincial Cancer Hospital Jilin Provincial Tumor Hospital Jingzhou First People's Hospital Liaoning Cancer Hospital & Institute Mianyang Central Hospital Nanchang University First Affiliated Hospital Ningbo No. 1 Hospital Shandong Cancer Hospital and Institute Shanghai Chest Hospital Shijiazhuang People's Hospital Sichuan Cancer Hospital and Research Institute Sun Yat-sen University The Affiliated Hospital of Qingdao University The First Affiliated Hospital of Zhengzhou University The Second Affiliated Hospital of AFMU Tianjin Cancer Hospital Tongji Hospital West China Hospital Xiangyang Central Hospital Xinxiang Central Hospital Yunnan Cancer Hospital Zhejiang Cancer Hospital Zhejiang University